Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

The management of Tyme Technologies, Inc. (the “Company”) will present at the Rodman& Renshaw 19th Annual Global Investment Conference on Monday, September11, 2017 at the Lotte New York Palace Hotel in New York, New York at approximately 9:00 a.m. EDT. The slides that the Company’s management will present are furnished herewith as Exhibit 99.1.

The information furnished to Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Set forth below is the exhibit to this Current Report on Form 8-K.

TYME TECHNOLOGIES, INC. Exhibit
EX-99.1 2 d399069dex991.htm EX-99.1 EX-99.1 SEPTEMBER 2017 Exhibit 99.1 Safe Harbor Statement Certain statements in this presentation and associated oral statements are “forward-looking statements” under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include the risk for the Company to complete its development work,…
To view the full exhibit click here

About Tyme Technologies, Inc. (OTCMKTS:TYMI)

Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.